PRECISIONLIFE
24.3.2021 09:02:13 CET | Business Wire | Press release
PrecisionLife today announces that it has acquired its long-term Danish technology development partner GenoKey ApS, bringing together the leaders in combinatorial analytics and large-scale genomic analysis, and enabling PrecisionLife to continue its expansion as an AI-enabled precision medicine company. Financial details of the paper-based transaction were not disclosed.
PrecisionLife’s platform, which includes technology developed with GenoKey, enables the company to gain unique insights into genes associated with disease, as biomarkers and as targets for drug discovery. PrecisionLife’s business model maximizes the impact of its platform by partnering with others as well as building a pipeline of proprietary assets in chronic diseases.
In addition to its expertise and IP, PrecisionLife will benefit from GenoKey’s strong relationships with the Danish health system and leading academic clinical research centers including Aalborg, Aarhus and Copenhagen. Recently, PrecisionLife joined the pan-European FEMaLe consortium led by researchers from Aarhus University, which is a €5.3M international EU Horizon 2020 project that aims to develop precision medicine approaches to improve the diagnosis, treatment and quality of life of patients with endometriosis.
PrecisionLife will maintain its core platform development operations at GenoKey’s site in Denmark with further team expansion in the region planned. GenoKey’s Chairman and co-founder, Hans-Christian Brahe Møller joins the board of the wholly-owned subsidiary, PrecisionLife ApS. GenoKey’s scientific advisors will become part of the PrecisionLife advisory group.
“The acquisition of GenoKey solidifies a long-term highly productive collaboration around core IP, and positions PrecisionLife for its next round of investment and growth as a leader in the delivery of precision medicine beyond cancer and rare disease” said Dr Steve Gardner, CEO of PrecisionLife.
The accuracy and additional insights generated by PrecisionLife’s combinatorial analytics platform have been validated in multiple chronic disease areas such as ALS, schizophrenia, asthma, type-II diabetes and endometriosis as well as severe COVID-19. During the pandemic, PrecisionLife was able to find significantly more signals in severe COVID-19 patient datasets than traditional Genome Wide Association Study (GWAS) methods used by international consortia with access to much larger data sets, uncovering unique avenues for therapeutic intervention (1) . These achievements are complimented by GenoKey’s collaboration with Professor Erling Mellerup and his team at Copenhagen University on bipolar and other neuropsychiatric disorders, initially sponsored by the Lundbeck Foundation.
Welcoming the transaction, Hans-Christian Brahe Møller, Chairman of GenoKey said, “This acquisition presents an exciting opportunity to ensure that GenoKey’s 10 years’ of pioneering analytics development can contribute to the global challenge of delivering new solutions for patients with unmet medical needs in chronic diseases, which represent a huge economic and social burden to healthcare systems and millions of patients around the world.”
1. COVID-19 studies, see https://www.medrxiv.org/content/10.1101/2020.06.17.20134015v2.full.pdf and https://www.medrxiv.org/content/10.1101/2021.02.08.21250899v1.full.pdf
About PrecisionLife
PrecisionLife is headquartered near Oxford, UK and has operations in Aalborg and Copenhagen, Denmark, Warsaw, Poland and Cambridge, MA, USA. The company’s unique combinatorial analytic platform generates more insights into the complex biology of chronic diseases, driving the next wave of precision medicine applications and finding new treatment opportunities for patients’ unmet medical needs. PrecisionLife partners with disease charities, clinical research groups, CROs, best of breed technology providers and pharma, biotech and healthcare companies to improve our knowledge of chronic disease biology. PrecisionLife operates an innovation engine that translates proprietary disease biology insights into new drug discovery programs, more successful and cost-effective clinical trials and more personalized clinical decision support tools.
For more information see https://precisionlife.com/
Follow us on LinkedIn (precisionlife ) and Twitter (@precisionlifeAI )
About GenoKey ApS
GenoKey was founded by Dr Gert Lykke Møller (now Chief Analytics Officer of PrecisionLife), Hans-Christian Brahe Møller and two colleagues. GenoKey pioneered the underlying mathematical approach that enables deep combinatorial analysis of genomic and other clinical and epidemiological patient data. Gert was the first to reduce this innovative approach to computational practice, and this has been developed in collaboration with PrecisionLife into a powerful analytical platform that enables the largest and most detailed precision medicine studies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom